PMID- 28889145
OWN - NLM
STAT- MEDLINE
DCOM- 20180516
LR  - 20181113
IS  - 1658-3175 (Electronic)
IS  - 0379-5284 (Print)
IS  - 0379-5284 (Linking)
VI  - 38
IP  - 9
DP  - 2017 Sep
TI  - Efficacy and adverse events of pirfenidone in treating idiopathic pulmonary 
      fibrosis.
PG  - 889-894
LID - 10.15537/smj.2017.9.19349 [doi]
AB  - To analyze the efficacy and adverse events  (AEs) of pirfenidone in idiopathic 
      pulmonary fibrosis (IPF) trials. Methods: MEDLINE, Cochrane Library, and 
      ClinicalTrials.gov were searched for studies published before June 2016. All 
      studies of clinical trials with the key words IPF or idiopathic pulmonary 
      fibrosis or lung fibrosis and pirfenidone or Esbriet were identified. Quality 
      assessment and data extraction nwere conducted by 2 independent researchers. A 
      meta-analysis of randomized controlled trials (RCTs) was performed, and relative 
      risk (RR) and 95% confidence intervals (95% CIs) were calculated.   Results: Five 
      studies were included in this review, involving 1568 participants. The 
      meta-analysis revealed that pirfenidone reduced the risk of decline in forced 
      vital capacity (FVC)% >/=10% from baseline (relative risk: 0.62; 95% CI: 0.51-0.76, 
      p less than 0.001). The pirfenidone group had a significantly higher rate of AEs 
      compared with the placebo group. Pirfenidone did not reduce mortality from any 
      cause significantly (odds ratio: 0.63; 95% CI: 0.36-1.09). Conclusions: This 
      study showed that pirfenidone could reduce disease progression as assessed by the 
      decline in FVC in IPF. Pirfenidone represents a suitable treatment option for 
      patients with IPF.
FAU - Ren, Hui
AU  - Ren H
AD  - Department of Outpatients, Sichuan Academy of Medical Sciences＆Sichuan Provincial 
      People's Hospital , Chengdu, Sichuan Province, China. E-mail. 2286772096@qq.com.
FAU - Wang, Kai
AU  - Wang K
FAU - Yang, Hao
AU  - Yang H
FAU - Gao, Lingyun
AU  - Gao L
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Saudi Arabia
TA  - Saudi Med J
JT  - Saudi medical journal
JID - 7909441
RN  - 0 (Placebos)
RN  - 0 (Pyridones)
RN  - D7NLD2JX7U (pirfenidone)
SB  - IM
MH  - Humans
MH  - Idiopathic Pulmonary Fibrosis/*drug therapy/physiopathology
MH  - Meta-Analysis as Topic
MH  - Placebos
MH  - Pyridones/adverse effects/*therapeutic use
MH  - Randomized Controlled Trials as Topic
MH  - Respiratory Function Tests
PMC - PMC5654021
EDAT- 2017/09/11 06:00
MHDA- 2018/05/17 06:00
PMCR- 2017/08/01
CRDT- 2017/09/11 06:00
PHST- 2017/09/11 06:00 [entrez]
PHST- 2017/09/11 06:00 [pubmed]
PHST- 2018/05/17 06:00 [medline]
PHST- 2017/08/01 00:00 [pmc-release]
AID - SaudiMedJ-38-889 [pii]
AID - 10.15537/smj.2017.9.19349 [doi]
PST - ppublish
SO  - Saudi Med J. 2017 Sep;38(9):889-894. doi: 10.15537/smj.2017.9.19349.